Cardinal Health, Inc. (NYSE:CAH) is one of the stocks from different market sectors that Jim Cramer commented on. Cramer highlighted the company’s noteworthy performance, as he commented:
“The drug distributors continue to relentlessly climb higher. There’s nothing, you know, people hate the pharma middleman. Even the president doesn’t talk, like… them. But I got to tell you, their stocks, they are juggernauts. Cardinal Health, Cencora, and McKesson, they were all up more than 40% last year. Cardinal is really the monster of that group.”
Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels
Cardinal Health, Inc. (NYSE:CAH) supplies branded, generic, and specialty medicines and provides pharmacy and specialty drug services. The company also makes and distributes medical and surgical products and procedure kits. Brown Advisory stated the following regarding Cardinal Health, Inc. (NYSE:CAH) in its third quarter 2025 investor letter:
“Cardinal Health, Inc. (NYSE:CAH), one of the three major U.S. drug distributors, continues to benefit from rising demand for complex specialty and biologic therapies, where it is expanding value-added service offerings. The company also serves adjacent markets such as third party logistics and the fast-growing nuclear medicine space. Its medical distribution business remains an execution turnaround story, with new management narrowing service gaps with peers and showing early progress in improving margins.”
While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
